Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Anlotinib, and Chemotherapy in Resectable NSCLC
NCT05400070Phase 2Active, not recruiting
- Sponsor
- Tangdu Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Primary endpoints: Pathological Complete Response up to 4 months and Safety of the treatment process. Started Mar 2021; status: active, not recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05400070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400070.